


OvRSeq Analysis Report for TCGA-13-1501

2023-12-01


The vulnerability map indicate based on BRCAness probability and CYT to C1QA ratio (C2C) indications with a high vulnerability (score) for response to combination immunotherapy with PARPi and immune checkpoint inhibitors.



Patient values

Feature	Value
BRCAness status	1 (0.96)
Infiltration status	Desert
Molecular subtypes	MES
BRCAness immunotype	noBRIT
Vulnerability score	2.62
Immuno phenoscore	1
CYT to C1QA ratio (C2C)	0.01
Angiogenesis Score	1

Molecular markers and TCGA-OV Reference Values. Marker gene expression levels and respective Q1 and Q3 levels (interquartile range) from the TCGA cohort.



Feature	Patient Value	TCGA IQR
CD274	0.53	1.32 (0.87-1.86)
GZMB	0.76	2.55 (1.62-3.51)
PRF1	0.60	1.73 (1.15-2.50)
C1QA	6.44	7.35 (6.41-8.18)
CD8A	0.94	1.90 (1.17-2.65)
IDO1	2.56	4.16 (2.80-5.45)
FOXP3	1.92	1.94 (1.32-2.52)
TREM2	4.65	4.83 (3.76-5.64)
STAT1	5.30	7.01 (6.21-7.55)
HLA-DRA	5.25	7.26 (6.30-8.00)
CXCL10	4.16	6.38 (5.03-7.54)

Selected signatures/pathway scores (ssGSEA) normalized using min-max scaling with reference to TCGA values; and quantified immune cell infiltrates (quanTIseq).

